Moderna (MRNA) Stock
Biotech company specializing in mRNA vaccines and treatments. Here's the price, business snapshot, and what's worth knowing about Moderna in August 2026.
Moderna, Inc. (MRNA) is a biotechnology company centred on messenger RNA (mRNA) technology, best known for its COVID‑19 vaccine. The company applies its platform to develop vaccines and therapeutics across infectious diseases (influenza, RSV, CMV) and oncology, aiming for faster design and scalable manufacturing. Investors should know Moderna’s prospects combine platform-driven upside with typical biotech risks: revenues can be lumpy, clinical trials are binary events, and regulatory approvals and competition (notably Pfizer/BioNTech) materially affect the outlook. The market capitalisation reflects the transition from pandemic-era demand to a broader commercial strategy. Moderna invests heavily in R&D and capacity, which can pressure margins in the near term but may support future growth if programmes succeed. This stock tends to be higher volatility and may suit investors with a longer timeframe and higher risk tolerance. This is general information, not personalised investment advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend holding Moderna's stock with a target price of $97.88, indicating potential for improvement.
Financial Health
Moderna is generating solid revenue and cash flow, indicating strong operational performance and financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform-driven growth
Moderna’s mRNA platform can speed development and scale production, offering potential for new products — though trial outcomes and approvals remain uncertain.
Pipeline diversification
Programmes in flu, RSV, CMV and oncology could broaden revenue streams, but each faces clinical and regulatory hurdles that create binary outcomes.
Commercial dynamics
Post‑pandemic demand, pricing and competition shape future sales; market conditions can change quickly and past performance is no guarantee of future results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
